Sign Up
OverviewAPI
The global biobetter market is projected to reach $150.75 billion by 2034, driven by advanced therapeutic biologics, scientific advancements, and regulatory support. Key companies like Roche, Amgen, and Pfizer are investing in biobetter development through strategies like mergers and acquisitions. The United States and Germany are identified as profitable markets for biobetter manufacturers due to the increasing incidence of chronic diseases and advanced medical facilities.

Ask a question